Company profile: Twelve Bio
1.1 - Company Overview
Company description
- Provider of CRISPR-Cas12a-based diagnostic technology for detecting and editing DNA sequences, leveraging an RNA-protein molecule where RNA identifies specific DNA targets and the protein acts as a biological scissor to cut and modify them.
Products and services
- CRISPR-Cas12a Diagnostic Technology: CRISPR-Cas12a-based system that detects any DNA sequence using RNA to identify specific targets, enabling precise, sequence-specific molecular diagnostics
- CRISPR-Cas12a DNA Editing Component: Protein-mediated assembly that changes any DNA sequence by cutting targeted sites, with Cas12a acting as biological scissors for precise, sequence-specific modification
- CRISPR-Cas12a RNA-Protein Complex: RNA-guided molecule that identifies specific DNA sequences and the protein cuts them, enabling both detection and modification in one integrated biological complex
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Twelve Bio
Mesa Labs
HQ: United States
Website
- Description: Provider of biological and chemical indicators; sterilization and disinfection monitoring solutions; validation accessories; incubators; and culture media to ensure compliance and validation of sterilization and disinfection processes, and high-quality measurement instruments and accessories that it acquires, develops, manufactures, and markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mesa Labs company profile →
Esperite
HQ: The Netherlands
Website
- Description: Provider of healthcare services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Esperite company profile →
Cellix
HQ: Ireland
Website
- Description: Provider of microfluidic pumping solutions, consumable biochips, software, and automated solutions for cell biology, microfluidics and nanofluidics, physics, chemistry, and cell and particle studies. Offerings include pulse-free syringe, pressure and recirculating pumps with PC control, VenaFlux for shear flow assays, the Inish Analyser for label-free cell counting, viability and transfection efficiencies, and disposable biochips for flow and droplet studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellix company profile →
Dualsystems Biotech
HQ: Switzerland
Website
- Description: Provider of proteomic services for industry and academia, offering mass spectrometry-based proteomics and ligand-receptor interaction platforms: LRC-TriCEPS to identify interactions on living cells for drug discovery and receptor identification, and HATRIC-LRC to find receptors for orphan ligands. Swiss biotech founded in 2000 with yeast two-hybrid technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dualsystems Biotech company profile →
BBI Group
HQ: United Kingdom
Website
- Description: Provider of diagnostic products to multiple industries, founded on superior gold reagents. A trusted partner to leading diagnostic and healthcare organisations for over 25 years, with three businesses delivering excellence in diagnostic assay development and manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BBI Group company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Twelve Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Twelve Bio
2.2 - Growth funds investing in similar companies to Twelve Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Twelve Bio
4.2 - Public trading comparable groups for Twelve Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →